Learning Objectives:

  1. Quantify the combined effects of SGLT2i, ns-MRA, and GLP-1RA on kidney disease
  2. Explore the physiology of these medications further
  3. Identify points of our current practice that we can change to improve the outcomes for our patients
Session date: 
12/22/2023 - 12:00pm to 1:00pm CST
Via Zoom
5841 S. Maryland Ave
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Gilad Guez, MD